申请人:Pfizer Inc
公开号:US20040092529A1
公开(公告)日:2004-05-13
The present invention relates to compounds of the formula I
1
and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R
1
, R
2
, R
3
, R
4
and R
5
are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.
本发明涉及公式I1的化合物及其药学上可接受的形式;其中X、Y、a、b、c、d、R1、R2、R3、R4和R5如本文所定义。此外,本发明还涉及包含公式I的化合物和药学上可接受的载体的药物组合物。此外,本发明还涉及使用本文所述的化合物和组合物治疗或预防哺乳动物中可通过拮抗CCR1受体治疗或预防的疾病或状况的方法。